Tessera Therapeutics vs Neuralink
Side-by-side comparison of AI visibility scores, market position, and capabilities
Tessera Therapeutics is developing Gene Writing technology to insert large therapeutic sequences directly into the genome without double-strand DNA breaks; raised $230M+ including a $100M Series B;
About
Tessera Therapeutics is a genomic medicine company founded in 2018 by Jacob Rubens, Brian Goodman, and colleagues at Flagship Pioneering (the life sciences venture creation firm behind Moderna) and headquartered in Cambridge, Massachusetts. The company is pioneering Gene Writing — a platform technology that uses mobile genetic elements (specifically RNA-guided integrases derived from retrotransposons) to write large DNA sequences directly into the human genome at targeted sites, without requiring double-strand DNA breaks. This approach is designed to overcome key limitations of first-generation gene editing technologies: CRISPR-Cas9 creates double-strand breaks that can introduce unintended mutations, and current gene editing tools are largely limited to small sequence corrections or knockouts rather than full gene insertions.
Pioneer of implantable BCIs with 12+ active human patients as of Sep 2025; raised $650M Series E in Apr 2026 led by ARK Invest and Sequoia at a ~$14.9B valuation; mass production underway.
About
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with paralysis to control digital devices directly with their thoughts. The company's first commercial product, the N1 implant, is a coin-sized device containing 1,024 electrodes that is surgically placed in the motor cortex. As of September 2025, twelve patients worldwide had received the N1 implant and were actively using it to control computers, smartphones, and robotic arms with neural signals alone.
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.